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Background: The basal ganglia (BG) are a complex network of subcortical nuclei involved in the coordination and
integration of the motor activity. Although these independent anatomical structures are functionally related, the
proteome present in each isolated nucleus remains largely unexplored. In order to analyse the BG proteome in a
large-scale format, we used a multi-dimensional fractionation approach which combines isolation of anatomically-defined
nuclei, and protein/peptide chromatographic fractionation strategies coupled to mass spectrometry.
Results: Using this workflow, we have obtained a proteomic expression profile across striatum and globus pallidus
structures among which 1681 proteins were located in caudate nucleus (CN), 1329 in putamen, 1419 in medial
globus pallidus (GPi), and 1480 in lateral globus pallidus (GPe), establishing a BG reference proteome to a depth of
2979 unique proteins. Protein interactome mapping highlighted significant clustering of common proteins in
striatal and pallidal structures, contributing to oxidative phosphorylation, protein degradation and neurotrophin
signalling pathways. In silico analyses emphasized specific pathways represented in striatal and pallidal structures
highlighting 5-hydroxytryptamine degradation, synaptic vesicle trafficking, and dopamine, metabotropic glutamate
and muscarinic acetylcholine receptor pathways. Additional bioinformatic analyses also revealed that: i) nearly 4% of
identified proteins have been previously associated to neurodegenerative syndromes, ii) 11% of protein set tends to
localize to synaptic terminal, and iii) 20% of identified proteins were also localized in cerebrospinal fluid (CSF).
Conclusions: Overall, the anatomo-proteomic profiling of BG complements the anatomical atlas of the human brain
transcriptome, increasing our knowledge about the molecular basis of the BG and the etiology of the
movement disorders.
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The basal ganglia (BG) and related nuclei consist of a
variety of subcortical cell groups involved primarily in
motor control, together with several roles in emotions
and executive functions and behavior [1,2]. The term BG
refers to nuclei embedded deep in the brain hemispheres
(striatum or CN-putamen) and globus pallidus (GP),
whereas related nuclei consist of structures located in
the diencephalon (subthalamic nucleus), and mesen-
cephalon (substantia nigra) [3]. The CN, the putamen,* Correspondence: esantamma@navarra.es
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article, unless otherwise stated.and the accumbens nucleus are all considered input nu-
clei, structures that receive incoming information from dif-
ferent sources such as cortex, thalamus, and substantia
nigra (SN). The medial globus pallidus (GPi), and the SN
pars reticulata (SNr) structures are the output nuclei, send-
ing BG information to the thalamus. Finally, intrinsic nuclei
such as the lateral globus pallidus (GPe), the subthalamic
nucleus (STN) and the substantia nigra pars compacta
(SNc) are located between the input and output nuclei [4].
Dopamine finely tunes striatal input as well as neur-
onal striatal activity, and modulates GPe, GPi, and STN
activity. In the motor circuit, the striatum receives gluta-
matergic afferents from the cortex and thalamus and
dopaminergic innervation from the SN. The putamen
projects inhibitory GABAergic axons to both pallidaled Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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fibers from the STN. The thalamus projects to the stri-
atum and STN and the dopaminergic fibers also reach
the GP, STN, thalamus, and brainstem [5].
Major cell types of BG neurons are highly specialized
and are classified based on morphological, physiological
and neurochemical properties. The striatum is the lar-
gest subcortical brain structure in the mammalian brain,
containing projection neurons (medium-sized spiny neu-
rons) and interneurons. Both types of cells are inhibitory
neurons that use γ-aminobutyric acid (GABA) as the
neurotransmitter [6]. Projection neurons could be also
divided according to their projection targets, into those
innervating the GPe nucleus and those projecting to the
GPi and SNr. Both types of projection neurons differ
also in the dopamine receptor subtype expressed and in
the ability to inhibit/activate the adenyl-cyclase pathway
[7]. At least, four types of GABAergic interneurons have
been characterized according to their electrophysio-
logical and neurochemical properties [8]. Both GP nuclei
are composed of sparsely distributed GABAergic neu-
rons with large somas, characterized by an enhaced ex-
pression of the calcium-binding protein parvalbumin [7].
In the last decade, different -omics strategies have been
used to understand the molecular organization and com-
plexity of different regions of the brain [9-12]. Specific-
ally, quantitative proteomics based on a combination of
2-DE or 18O labelling with MS has been used to describe
protein profiles of striatum in rat and macaque models of
L-DOPA-induced dyskinesia [13-16] and also in several
models of Huntington’s and Parkinson’s diseases [16-25].
In particular, proteomic technologies have been also
applied in the analysis of the substantia nigra derived
from parkinsonian subjects [26-28]. On the other hand,
MS-based qualitative proteomics has been employed to
profile the murine striatum proteome and secretome
[29,30]. However, despite these efforts to identify and
catalogue part of the murine proteins present in BG, only
a very limited number of human proteins have been char-
acterized in these independent and functionally related
substructures that compose the BG.
Here we used anatomical, protein, and peptide frac-
tionation strategies coupled to nanoLC-MS/MS to per-
form a shotgun proteome-wide analysis of the human
globus pallidus (GPe and GPi), CN, and putamen pro-
teomes in depth, and present a reference proteome map
of the human BG. We report the identification of 2979
protein species in basal nuclei derived from 6 healthy
patients. Using integrated in-silico studies, we provide an
extensive overview of molecular functions based on gene
ontology term enrichment, pathways studies, and inter-
actome network analysis. This protein compilation present
in human BG paves the way toward the complete molecu-
lar characterization of subcortical structures, and may beuseful to understand the molecular basis of neurodegener-
ative movement disorders.
Results
Large-scale identification of human basal ganglia
proteomes by mass spectrometry
In the present study, we have used autopsy specimens of
the right BG structures from six healthy human brains
with the final goal to obtain a profound insight into the
protein content and protein function of the nuclei that
compose the BG. To reduce protein complexity, we used
an integrated experimental workflow combining anatom-
ical fractionation, protein IEF, and chromatographic-based
methods coupled to mass spectrometry (Figure 1). For
each basal nucleus, proteins were separated by IEF and the
gel was sliced in 25 portions followed by in-gel trypsin
digestion. The second approach involved in- solution
digestion followed by off-line RP-LC at basic pH to separ-
ate the peptide mixture in 20 fractions. Replicate mass
spectrometry measurements were performed in all peptide
fractions for each basal nucleus. MS/MS data from each
substructure were processed to identify peptides that gave
rise to observed spectra, and proteins were inferred based
on identified peptides. The number of non-redundant pro-
teins identified with at least two unique peptides ranged
from 1681 proteins for CN, 1329 for putamen, 1419 for
GPi, and 1480 for GPe generating a BG reference prote-
ome map of 2979 unique protein species, identified with a
FDR lower than 1%. Complete lists of identifications and
their corresponding scores are presented in Additional
file 1: Table S1, Additional file 2: Table S2, Additional
file 3: Table S3, Additional file 4: Table S4 and in Pro-
teomeXchange repository (http://proteomecentral.proteo-
mexchange.org). As shown in Figure 2A, 30% of the
dataset (916 proteins) was exclusively detected in striatal
structures (CN and putamen) while 26% (776 proteins)
was identified only in pallidal nuclei (GPe and GPi). On
the other hand, 532 proteins (18% of the protein set) over-
lapped between the four regions. According to Genetic
Association Database [31], 100 striatal and 88 pallidal pro-
teins have been previously linked to neurodegenerative
syndromes such as schizophrenia, Parkinson’s disease,
Alzheimer’s disease, and amyotrophic lateral sclerosis
(Figure 2B and Additional file 5: Table S5). The integrated
BG proteome dataset was also compared with previously
published lists of human CSF proteome descriptions
[32,33]. Interestingly, 599 proteins (20% of the protein set)
were found to exist in both the BG and CSF proteomes
(Figure 2C). A subset of these proteins is known to be in-
volved in a plethora of central nervous system functions
(Additional file 6: Table S6) and some of them are impli-
cated in the development of neurological diseases such
as Alzheimer’s, Parkinson’s, and Huntington’s diseases
(Additional file 6: Table S6).
Figure 1 An overview of the workflow used for identification of the BG proteomes.
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in striatum and globus pallidus
To enhance the analytical outcome of proteomic experi-
ments, we have performed a proteome-scale interaction
network merging the 532 common proteins detected
in GPe, GPi, CN, and putamen using the STRING soft-
ware [34]. This database includes interactions from
published literature describing experimentally studied
interactions, as well as those from genome analysis using
several well-established methods based on domain fu-
sion, phylogenetic profiling and gene neighbourhoodconcepts. Accordingly, a confidence score for every pro-
tein–protein association was assigned to the network. A
higher score was assigned when an association is sup-
ported by several types of evidence. To minimize false
positives as well as false negatives, all interactions tagged
as “low-confidence” (<0.4) in STRING database have
been eliminated from this study. Thus, the final network
is composed by 335 nodes (proteins) and 941 edges (in-
teractions) (Figure 3, Additional file 7: Figure S3 and
Additional file 8: Table S7), establishing the first com-
prehensive interactomics map for the BG proteome. The
Figure 2 Venn diagram of common and unique proteins
between BG structures. A) The distribution of common and
distinct proteins, identified by 2 or more peptides, in CN, putamen,
GPe, and GPi is shown. B) Graph showing the number of proteins
associated with neurodegenerative syndromes according to Genetic
Association Database. ALS, amyotrophic lateral sclerosis. C) Overlap
of integrated BG proteome characterized in this study with CSF
proteome datasets [32,33].
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tral interplay with highly connected interactions and sev-
eral sparsely connected sub-networks (Figure 3). The
main central subset is composed by 27 nodes and is re-
ferred as the oxidative phosphorylation network (Figure 3).
Other overlapping sub-networks are composed by inter-
connected nodes linked to GTP binding and neurotrophin
signalling pathway and also by nodes involved in protein
degradation (Figure 3).Contribution to the repertoire of human brain proteome
Protein identification data from the current study
was compared with previous proteomic descriptions
derived from large-scale proteomic studies of intimately
related structures from human limbic system such as
amygdala [35], hippocampus [36], olfactory bulb [37], pi-
tuitary gland [38], thalamus [39], and sustantia nigra
[26,28,40-42] (Figure 4). On the other hand, combining
the information stored in three repositories containing
the largest number of synapse specific proteins (G2Cdb,
Synaptome DB, and SynsysNet) [43-45], we have con-
structed an integrative synaptic proteome database con-
taining 2705 synaptic protein-coding genes (Additional
file 9: Table S8). Then, we have compared our protein
compilation lists with the synaptic proteome database,
detecting expression of 288 and 268 synaptic proteins in
striatal and pallidal structures respectively (Figure 4 and
Additional file 9: Table S8). In total, 346 proteins identi-
fied in BG (11% of the dataset) tend to localize to synap-
tic terminal.
Functional metrics of human BG proteomes. Gene
ontology analysis
To extract biological knowledge, the striatal and pallidal
proteome datasets were functionally categorized based
on Gene Ontology (GO) annotation code using DAVID
software [46]. From striatal and pallidal datasets, 1393
and 1308 identifiers were considered for further analysis.
With respect to the biological process and molecular
function categories, an enrichment analysis has been
performed against Homo Sapiens background using
functional annotation clustering provided in DAVID
tool. Respects to biological process ontology, 24 clusters
are significantly enriched in BG nuclei respect to human
genome (Additional file 10: Table S9). Some of the most
significantly enriched biological processes included long-
term strengthening of neuromuscular junction, aerobic
respiration, regulation of ubiquitin-protein ligase activity,
and glucose and ATP catabolism. Representative bio-
logical process categories from each cluster in striatal
and pallidal structures are shown in Additional file 7:
Figure S4.
Respects to molecular function ontology, 10 clusters
are significantly enriched in the BG proteome dataset
(Additional file 11: Table S10). Intramolecular oxidore-
ductase, aminoacyl-tRNA ligase, hydrogen ion trans-
membrane transporter, and ATPase activities, were the
most significantly enriched molecular functions in our
dataset. Representative molecular function categories
from each cluster in striatum and globus pallidus are
represented in Additional file 7: Figure S5. Respect to
cellular component ontology, a significant proportion of
striatal and pallidal proteins consisted of cytosolic, mito-
chondrial, cytoskeletal proteins together with plasma
Figure 3 Protein interactome network for shared proteome between pallidal and striatal structures. Using the STRING software, proteins
are represented with nodes and the interactions with continuous lines to represent direct interactions (physical), while indirect ones (functional)
are presented by interrupted lines. Stronger associations are represented by thicker lines.
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S6A and Additional file 11: Table S10). Additionally, a
neuron-specific cell component analysis was also per-
formed, detecting proteins associated to neuron projec-
tion, synapse, axon, and dendrites between others
(Additional file 7: Figure S6B and Additional file 11:
Table S10).
Functional metrics of human BG proteomes. Pathways
analysis
A complementary analysis of biological processes was
performed with a search of KEGG pathways [47], that
are over-represented in human BG nuclei. The 35 path-
ways represented with a high statistical significance (fold
enrichment >1.5; EASE p-value <0.01) are shown in
Additional file 12: Table S11. Four of these pathways are
clearly related to neurological disorders such asParkinson’s, Alzheimer’s, Huntington’s, and Prion dis-
eases. Among the KEGG pathways, oxidative phos-
phorylation, proteasome, and neurotrophin signalling
pathway, are of particular interest because they partially
reinforce the BG interactome map. Strong representa-
tion of carbohydrate, lipid, and amino acid metabolism,
together with the regulation of neurological system
process such as lon-term potentiation/depression and
endocytosis, parallels with previous observations that
GO Terms “glucose metabolism/catabolism”, aminoacyl-
tRNA ligase activity”, “Fatty acid beta oxidation”, “regu-
lation of synaptic transmission” and “neurotransmitter
transport” are highly enriched in basal nuclei. In order
to gain a more detailed description of the molecular
mechanisms represented in striatum and globus pallidus,
subsequent analyses were performed to explore the stri-
atal and pallidal proteome distributions across specific
Figure 4 Intersection of proteins derived from proteomic expression profiling of human limbic structures and synaptosomes with
proteins identified in BG nuclei. (upper) Protein expression data reported in amygdala [35], hippocampus [36], olfactory bulb [37], pituitary
gland [38], thalamus [39], and sustantia nigra [26,28,40-42] have been considered. Striatum dataset contains proteins detected in CN and
putamen while GP dataset encompasses proteins identified in the lateral and medial segments (GPe and GPi). Numbers represent the number of
shared proteins in the respective overlapping areas. (lower) Venn diagrams representing the overlap between the “synaptic proteome” composed
by the three major databases on synaptic proteins (C2G, SynsysNet, and Synaptome DB) [43-45] and the striatal and pallidal proteomes
characterized in this study.
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Interestingly, as shown in Figure 5, some statistically
over-represented processes in both structures were dir-
ectly relevant to neurotransmitter release, electrical ma-
chinery and synaptic plasticity (Additional file 13: Table
S12). Specifically, we found a significant enriched path-
way focused on gamma-aminobutyric acid (GABA) syn-
thesis in pallidal dataset while in the case of striatum,
most of enriched pathways are related to beta-adrenergic
receptors and endogenous opioid system. The observa-
tion that there are protein clusters differentially enrichedbetween striatal and pallidal structures related to specific
biological process and molecular function ontologies is
not relevant since all protein clusters were represented
in both structures but their statistics did not reach the
minimum statistical requirements.
BG proteomics as a complement of the human brain
transcriptome
We have correlated our proteomic fingerprints with
the anatomical map of the human brain transcriptome
stored in the Allen Brain Atlas [11] in order to analyze
Figure 5 Specific-Neuronal Pathway analysis for the BG proteomic
expression profile. Protein clusters significantly enriched in striatal and
pallidal proteome datasets (fold enrichment >1.5, EASE p-value <0.01)
are shown. Fold enrichment refers to the number of relevant striatal
or pallidal protein species represented in each cluster relative to
random expression of all genes in the human genome. A complete
characterization of each cluster is shown in Additional file 13: Table S12.
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different levels of organization. First, we have inter-
locked each BG proteomic expression profiling with
transcriptomic data from genes with brain-wide (global) or
within structure (local) ubiquity (Figure 6 and Additional
file 14: Table S13). Second, transcriptome expression data
from genes specifically expressed in striatum and globus
pallidus [11] was checked against the anatomo-proteomicexpression data derived from BG structures (Figure 6 and
Additional file 14: Table S13). As shown in Figure 6, we
have detected pallidal protein expression for 81 and 86
genes (in GPe and GPi respectively) and striatal protein
expression for 100 and 75 genes (in CN and putamen re-
spectively) with ubiquitous expression across human brain
(Additional file 14: Table S13). In contrast, proteomic
screens have revealed pallidal protein expression for nearly
40 genes with region-specific expression, whereas in the
case of striatum, we have obtained protein expression data
for 49 and 42 region-specific genes in CN and putamen re-
spectively (30 genes common in both structures) (Figure 6
and Additional file 14: Table S13). From 172 region-
specific genes that express in globus pallidus, we have
obtained protein evidence for 5 and 7 genes in GPe and
GPi respectively (4 common proteins in both structures)
whereas 13 out of 160 region-specific genes that express in
striatum have been detected at protein level in CN (9 genes
in the case of putamen) (Figure 6 and Additional file 14:
Table S13).
Specific protein products of major cell type markers in BG
datasets
Additional analyses were performed to detect cell type-
specific information in BG by detecting protein evidence
for well-known transcriptomic markers of major cell
classes [49,50]. Protein expression of marker genes of
oligodendrocytes (CNP, HSPA2, MBP, MOG, PLP1),
astrocytes (ATP1A2, GFAP, GLUL, HAPLN1, SLC4A4,
AHCYL1), and neurons (PGM2L1, GDA, MAP2,
MAP1B, SCG2, SNAP25) was detected in all four struc-
tures (Table 1). In addition, protein products of other
oligodendrocyte marker genes such as BCAS1, ENPP6,
and PPP1R14A were found in pallidal structures. Protein
expression was also detected for additional astrocyte
markers such as SLC1A2 (in GPe, GPi, and putamen),
ALDOC (in GPi, CN, and putamen), METTL7A (in GPi
and putamen), and ALDH1L1 in CN. Respect to neur-
onal markers, protein products for PLCXD3, SLC12A5,
NRCAM, and NRXN1 genes were also identified across
striatal and/or pallidal structures (Table 1).
Discussion
The complex structural and functional organization of
the brain is reflected by the selective spatial and tem-
poral expression of its resident proteins [10]. Given its
segmented functions, characterization of protein profiles
within specific regions of the adult brain forms an essen-
tial part of unearthing the molecular basis for structure
specialization and perturbation associated with neuro-
logical disorders.
In this work, we have performed an anatomically com-
prehensive proteomic mapping of human BG in order to
gain new insight into the protein content and protein
Figure 6 Anatomical correlation between pallidal and striatal proteomic expression profiling and human brain transcriptome. Protein
datasets derived from BG structures were intersected with transcriptomic expression profiling obtained in human brain [11]. In this case, we
have considered genes with brain-wide expression (ubiquitous expression) or within local ubiquity (region-specific expression) in neocortex,
myelencephalon, hippocampal formation, dorsal thalamus, striatum, mesencephalon, cerebellar cortex, pontine tegmentum, cingulate gyrus, basal
pons, claustrum, and globus pallidus [11]. See Additional file 14: Table S13 for more details.
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mentary protein and peptide fractionation methods
coupled to tandem mass spectrometry, we have identi-
fied 2979 unique proteins in BG corresponding to more
than 5900 protein expression features distributed across
CN, putamen, GPe, and GPi.
Although striatal and pallidal structures are composed by
different specialized types of neurons with highly distinct
transcriptomic profiles [6,7,11], more than 500 proteins
have been commonly detected in CN, putamen, GPe, andGPi structures. This panel of proteins takes part in a global
protein interactome map, indicating that oxidative phos-
phorylation, protein degradation, and neurotrophin signal-
ling are active pathways mediated by overlapping protein
interactors in striatal and pallidal structures.
Although our study has uncovered many intricacies in
protein expression in BG, there are potential limitations
of our study that warrant discussion. We analysed dis-
sected tissues that contained multiple cell types, thus
diluting the proteomic contribution of any one specific
Table 1 Detection of specific protein products of major cell type markers in basal nuclei by proteomics
Markers Protein products Code Gpe Gpi CN Put.
OLs
CNP 2′,3′-cyclic-nucleotide 3′-phosphodiesterase P09543 ++ ++ ++ ++
HSPA2 Heat shock-related 70 kDa protein 2 P54652 ++ ++ ++ ++
MOG Myelin oligodendrocyte glycoprotein Q5STM1 ++ ++ ++ ++
PLP1 Proteolipid protein 1 A8K9L3 ++ ++ ++ ++
MBP Isoform 3 of Myelin basic protein P02686-3 ++ --- ++ ++
Myelin basic protein P02686 --- ++ --- ---
BCAS1 Isoform 2 of Breast carcinoma-amplified sequence 1 O75363-2 ++ --- --- ---
ENPP6 Ectonucleotide pyrophosphatase/phosphodiesterase member 6 Q6UWR7 --- ++ --- ---
PPP1R14A Protein phosphatase 1 regulatory subunit 14A Q96A00 --- ++ --- ---
Astrocytes
ATP1A2 Sodium/potassium-transporting ATPase subunit alpha-2 B1AKY9 ++ ++ ++ ++
GFAP Glial fibrillary acidic protein P14136 ++ ++ ++ ++
GLUL Glutamate-Ammonia Ligase A8YXX4 ++ ++ ++ ++
HAPLN1 Hyaluronan and proteoglycan link protein 1 P10915 ++ ++ ++ ++
AHCYL1 Putative adenosylhomocysteinase 2 O43865 ++ ++ ++ ++
ALDOC Fructose-bisphosphate aldolase C P09972 --- ++ ++ ++
SLC4A4 Solute carrier family 4 Na(+)/HCO3(-) cotransporter 4 isoform 2 Q9Y6R1-2 ++ --- ++ ---
Solute carrier family 4 Na(+)/HCO3(-) cotransporter 4 Q9Y6R1 --- --- --- ++
Solute carrier family 4 Na(+)/HCO3(-) cotransporter 4 variant A5JJ20 --- ++ --- ---
SLC1A2 Excitatory amino acid transporter 2 P43004 ++ ++ --- ---
Solute carrier family 1, member 2 A2A2U1 --- --- --- ++
METTL7A Methyltransferase-like protein 7A Q9H8H3 --- ++ --- ++
ALDH1L1 Cytosolic 10-formyltetrahydrofolate dehydrogenase O75891 --- --- ++ ---
Neurons
PGM2L1 Glucose 1,6-bisphosphate synthase Q6PCE3 ++ ++ ++ ++
GDA Guanine deaminase Q9Y2T3 ++ ++ --- ++
Guanine deaminase isoform 3 Q9Y2T3-3 --- --- ++ ---
MAP2 Isoform 3 of Microtubule-associated protein 2 P11137-3 ++ ++ ++ ++
MAP2 protein (Fragment) Q6NYC5 ++ ++ ++ ++
MAP1B Microtubule-associated protein 1B P46821 ++ ++ ++ ++
SCG2 Secretogranin-2 P13521 ++ ++ ++ ++
SNAP25 Synaptosomal-associated protein 25 P60880 ++ ++ ++ ++
SLC12A5 Solute carrier family 12 member 5 Q9H2X9 ++ --- --- ---
cDNA FLJ75342, similar to solute carrier family 12 member 5 A8K143 --- ++ ++ ++
Isoform SNAP-25a of Synaptosomal-associated protein 25 P60880-2 --- --- ++ ++
PLCXD3 similar to PI-specific phospholipase C, X domain containing 3 B3KXD1 ++ --- ++ ++
NRCAM Isoform 2 of Neuronal cell adhesion molecule Q92823-2 --- ++ --- ---
Neuronal cell adhesion molecule Q92823 --- --- --- ++
NRXN1 Neurexin-1-alpha Q9ULB1 --- --- ++ ++
(++) indicates protein evidence and (---) non-detected. Code refers to the UniProtKB/Swiss-Prot entry for each protein. OLs, Oligodendrocytes.
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so far is not sufficient to investigate the full magnitude of
proteomic expression in BG. Moreover, we have employedpooled samples for each independent substructure. Al-
though all individuals were males of similar age and
ethnicity, our data do not capture population or sex
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tome is highly dynamic during neurodevelopment [10,11],
additional proteomic studies employing post-mortem
brains of clinically unremarkable donors representing
males and females with different ages and ethnic back-
grounds are necessary to estimate the consistency of the
proteomic profile obtained in this study.
One of the goals of the present study was to generate
extensive and robust data on the functional groups of pro-
teins present in human BG. To identify biologically rele-
vant pathways from large-scale BG proteome data, we
have undertaken a system biology approach performing
different molecular network and pathways analysis using
gene ontologies, KEGG pathways, and PANTHER classifi-
cation system [46-48]. Although each bioinformatics plat-
form produced diverse results, they commonly point out
that tricarboxylic acid cycle, ubiquitin proteasome pathway
and energy metabolism are the general over-represented
processes in basal nuclei as might be expected given the
high metabolic demands of neurons.
In agreement with different brain proteomic studies
[32,35,37], a high proportion of identified proteins
present catalytic and binding activities. We have not de-
tected a clearly distinguishable pattern of molecular cat-
egories between striatal and pallidal structures. Several
reasons may explain the functional parallelism observed
in both structures. First, our workflow is based on ana-
lysing un-fractionated tissue homogenates using a Q-
TRAP instrument [51] without employing previous
sequential extraction of proteins (for example enriched
organelle fractions, synaptosomes, etc.). This implies
that our proteomic datasets may correspond to highly
abundant proteins and housekeeping enzymes and tend
to represent the majority of proteins identified in unfrac-
tionated neural tissue, hampering the identification of
less abundant proteins with functional relevance. Future
studies employing high-resolution instruments will in-
crease the quality of BG proteome data in terms of high
resolving power, mass accuracy, and high sequencing
speed, generating novel proteomic data with high impact
from a functional point of view [52,53]. Second, a high
proportion (30%) of pallidal and striatal proteomes en-
compasses uncharacterized, putative or predicted pro-
teins based on genomic sequence data, limiting the
extraction of functional information from bioinformatics
resources. This is in accordance with data obtained in
human cortex, thalamus, and amygdala where also more
than 20% of the proteins identified by shotgun prote-
omic methods could not be assigned to biological pro-
cesses [32,35,39,54]. However, we have obtained a cell
type-specific information in basal nuclei identifying pro-
tein products for well-known markers of major cell clas-
ses derived from large-scale transcriptomic studies
[49,50] indicating that shotgun proteomic approachesmay be useful to identify specific protein isoforms of cell
markers, obtaining complementary information that
adds value to the conventional detection by immunohis-
tochemical staining.
We wish to emphasize that even though certain pro-
teins were identified in a particular BG structure, this
does not necessarily imply their absence in other nuclei
(see Additional file 15: Figure S7). Our data indicate that
a considerable proportion of this protein list was identi-
fied with a low number of peptides suggesting that the
discovery of this subset of proteins in a specific region
may be due to technical bias rather than specific protein
enrichment with respect to other structures.
We have obtained a deep functional analysis of the
striatum and globus pallidus, detecting a plethora of
neuronal molecular events enriched in basal nuclei. In
agreement with high throughput proteomic analyses of
other brain regions [32,37], enriched functional categor-
ies focused on carbohydrate, lipid, and amino acid me-
tabolism were also detected in striatum and globus
pallidus. In addition, we have found a considerable pro-
portion of proteins (11% of the dataset) that tends to
localize to synaptic terminal suggesting a potential role
in the regulation of synaptic transmission and neuro-
transmitter transport. For example, functional analyses
allowed us to classify different set of proteins in specific-
neuronal pathways across pallidal and striatal structures
such as serotonin degradation (8 proteins), dopamine re-
ceptor (30 proteins), metabotropic glutamate receptor
(18 proteins), muscarinic acetylcholine receptor (22 pro-
teins), and endogenous opioid system (10 proteins).
In order to expand our knowledge about the global
system biology of human brain, we interlocked regional
transcriptomic and proteomic signatures by focusing our
analyses on genes with global or local ubiquity [11]. Our
anatomo- proteomic analysis partially complements the
human brain transcriptome since we have obtained pro-
tein expression data for an appreciable number of genes
with proven transcriptomic evidence in basal nuclei and
other structures across the human brain. Specifically,
qualitative proteomics allow us to detected protein
expression (in GPe and GPi structures) for 8 genes
(Thiomorpholine-carboxylate dehydrogenase, RuvB-like
2, Calcium/calmodulin-dependent 3′,5′-cyclic nucleotide
phosphodiesterase 1B, Hyaluronan and proteoglycan link
protein 1, Neuronal pentraxin-1, Synaptic vesicle glyco-
protein 2B, Ephrin type-A receptor 6 and CaM kinase-like
vesicle-associated protein) that tend to be differentially
regulated between both pallidal structures [11].
On the other hand, in silico analysis points out that
nearly 4% of identified proteins in BG have been previ-
ously associated to neurodegenerative syndromes, and
20% of identified proteins were also localized in cerebro-
spinal fluid (CSF) from healthy subjects [33,55]. From
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identify the presence of brain tissue analytes in CSF, a
readily accessible resource for biomarker development
pipelines. Therefore, this comprehensive BG protein
dataset may serve as a reference list of human BG prote-
ome for biomarker research of movement disorders and
other neurodegenerative diseases, being a useful resource
to establish quantitative targeted analysis of potential BG
protein biomarkers by MRM (Multiple Reaction Monitor-
ing) assays [56,57].
Conclusions
We have carried out, to the best of our knowledge, the
first comprehensive analysis of the proteome present in
human caudate nucleus, putamen, GPe, and GPi. Our
results provide a broad functional analysis of 2979 non-
redundant striatal and pallidal proteins, being the first
step toward the complete characterization of the tangled
molecular architecture that composes de BG. This mo-
lecular fingerprint together with previous proteomic
profiling of specialized brain regions [32,35-39,54,58-61]
contribute to the repertoire of the human brain prote-
ome, providing fundamental information for the recently
officially launched Human Proteome Project and the
BRAIN Initiative [62,63]. Taking into account that the
central nervous system poses many specific challenges in
terms of proteomics, given the large number of different
neuronal cell types that are intermixed and that exhibit dis-
tinct patterns of gene and protein expression [10,11,64], the
development of specific isolation protocols of single-cell
types together with novel developments in shotgun prote-
omic strategies [65] will allow to explore the proteome pro-
filing of each subcortical nucleus individually, boosting the
molecular knowledge of the BG.
Methods
Sample collection
According to the Spanish Law 14/2007 of Biomedical
Research, inform written consent form of the Neuro-
logical Tissue Bank of Navarra Health Service was ob-
tained for research purposes from relatives of patients
included in this study. The 6 patients were male
and ages ranged from 29 to 61 years, with no known
neuropsychiatric or neurological history (control cases)
(Additional file 7: Figure S1). According to standard
practices in place at the neurological tissue banks, the
left cerebral hemisphere was progressively frozen and
stored at −80°C (post-mortem-interval: 6-15 h). The
diagnosis was carried out on the left cerebral hemi-
sphere. Therefore, the BG assessed in this study were
the right ones. Following fixation in 10% formaldehyde
for approximately three weeks, the brains were sectioned
according to the recommendation guide proposed
by BrainNet Europe [66]. After a macroscopic study,immunohistochemistry analysis was performed in differ-
ent brain regions using specific antibodies against Tau
protein, β amyloid, TDP-43, PrP, α-synuclein, ubiquitin
and α- β crystalline. These brains did not show signifi-
cant pathology and were considered to be healthy. In
particular, the immunohistochemical study of the BG
showed normal tissue without appreciable abnormalities.
The recognition of basal ganglia structure by the neuro-
pathologists was as follows: the caudate nucleus (CN) is
a C-shaped structure that is closely associated with the
lateral wall of the lateral ventricle. The putamen is also a
large structure that is separated from the CN by the an-
terior limb of the internal capsule. The globus pallidus
(GP) is divided into two segments: the internal (or med-
ial) segment and the external (or lateral) segment. Both
are separated by the medial medullary lamina. The GP is
separated from the putamen by a thin layer of white
matter called the lateral medullary lamina. A representa-
tive image of BG is shown in Additional file 7: Figure S2.
Sample preparation for proteomic analysis
BG specimens were obtained from frozen brain sections
using sterile biopsy punches (size: 3–4 mm) and homog-
enized in lysis buffer containing 7 M urea, 2 M thiourea,
4% (w/v) CHAPS, 50 mM DTT. The homogenates were
spinned down at 100.000 × g for 1 h at 15°C. Protein
concentration was measured in the supernatants with
the Bradford assay kit (Biorad). Prior to proteomic
analysis, the individual BG samples were grouped into 4
independent pools (GPe, GPi, putamen, and CN) con-
taining ~120 μg of protein from 6 individual samples
each one.
Peptide fractionation by HPLC
Protein material was precipitated using methanol/
chloroform. Pellets (~700 μg/pool) were dissolved in
100 mM Tris, pH 7.8, and 6 M urea. Reduction was per-
formed by addition of DTT to a final concentration of
10 mM and incubation at 25°C for 1 h. Subsequent
alkylation by 30 mM iodoacetamide was performed for
1 h in the dark. An additional reduction step was per-
formed by 30 mM DTT, allowing the reaction to stand
at 25°C for 1 h. Proteins were digested for 4 h with Lys-
C (Promega) at 37°C (enzyme:protein, 1:140 w/w). The
mixtures were then diluted to 0.6 M urea using MilliQ-
water, and after trypsin addition (Promega) (enzyme:pro-
tein, 1:50 w/w), the sample was incubated at 37°C for
18 h. Digestion was quenched by acidification with
acetic acid. The digestion mixture (~350 μg protein) was
dried in a SpeedVac, reconstituted with 40ul of 5 mM
ammonium bicarbonate (ABC) pH 9.8, and injected to
an Ettan LC system with a high pH stable X-Terra RP18
column (C18; 2.1 mm × 150 mm; 3.5 μm) (Waters) at a
flow rate of 40 μl/min. Peptides were eluted with a
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(A, 5 mM ABC in water at pH 9.8; B, 5 mM ABC in
acetonitrile at pH 9.8). 16–18 fractions were collected,
evaporated under vacuum and reconstituted into 15 μl
of 2% acetonitrile, 0.1% formic acid, 98% water.
Protein fractionation by isoelectric focusing (IEF)
Approximately 500 μg of each pooled sample was pre-
cipitated with methanol/chloroform. The pellet were re-
suspended in 300 μl of IEF rehydration buffer (7 M urea,
2 M thiourea, 2% CHAPS, 50 mM DTT, 0.5% Bio-Lyte
3/10 ampholyte) and loaded on 17 cm pH 3–10 IPG
strip in a focusing tray. Isoelectric focusing was per-
formed on a Bio-Rad PROTEAN IEF system (Bio-Rad).
Conditions for performing IEF were as follows: after re-
hydration of the IPG strip for 12 h at 50 V and 20°C, the
run was started at 250 V for 15 min. followed by rapid
voltage ramping to 8000 V without exceeding 50 A/strip.
The IEF run was finished when the voltage reached
35,000 Vhr. The voltage was held at 500 V until the run
was stopped. The IEF run was performed at 20°C. Each
entire IPG strip was divided into 25 equal parts (~0.7 cm
each) for in-gel reduction, alkylation, and digestion. In-gel
tryptic digestion was performed with 20 ng/μl trypsin in
50 mM ammonium bicarbonate for 12 h at 37°C. The
resulting tryptic peptides were extracted with 5% formic
acid, 50% acetonitrile and 5% formic acid, 85% acetonitrile.
Peptide mixtures were completely dried in a SpeedVac
and resuspended in 20 μl 98 % MilliQ-H2O, 2 % aceto-
nitrile, and 0.1 % formic acid.
nanoLC-MS/MS analysis
For each fraction, a total volume of 5 μl of tryptic pep-
tides was injected with a flow rate of 300 nL/min in a
nanoLC Ultra1D plus (Eksigent). The column and the
autosampler were maintained at a temperature of 40°C
and 4°C respectively. A trap column Acclaim Pep-
Map100 (100 μm × 2 cm; C18, 5 μm, 100 Å) and an ana-
lytical column Acclaim PepMap RSLC (75 μm × 15 cm,
C18, 2 μm, 100 Å) (Dionex) were used following the
next gradient: 0–1 min (2% Buffer B), 1–110 min (2–
30% Buffer B), 110–120 min (30–40% Buffer B), 120–
125 min (40-90% Buffer B), 125–130 min (90% Buffer
B), 130–132 min (90-2% Buffer B) and 132–150 min (2%
Buffer B) (Buffer B (100% acetonitrile, 0.1% formic acid),
Buffer A (0.1% formic acid)). MS analysis was performed
on a Q-TRAP 5500 system (ABSciex) with a NanoSpray®
III ion source (ABSciex). The mass spectrometer was
operated in positive ion mode at unit resolution. Each
fraction was analyzed twice in technical replicates. For
MS/MS analysis, survey scans were acquired from m/z
400 to 1000 with up to 6 precursors selected for MS/MS
from m/z 230 to 1000 using dynamic exclusion, and
the rolling collision energy was used to promotefragmentation. MS/MS data acquisition was performed
using Analyst 1.5.2 (AB Sciex) and spectra files were proc-
essed through Protein Pilot™ Software (v.4.0.8085-
ABSciex) using Paragon™ Algorithm (v.4.0.0.0) for data-
base search against the concatenated target-decoy UniProt
human database (Database: uniprot_sprot_20100622). For
each substructure, 82–86 runs were processed sequentially
with output files for each individual fraction and a
merged, non-redundant output file generated for protein
identifications. To minimize the false positive identifica-
tion of proteins, an unused ProtScore ≥2 (corresponding
to 99% confidence) was used as the qualification criteria.
False discovery rate (FDR) was performed using a non-
lineal fitting method [67] and displayed results were those
reporting a protein level-FDR lower than 1%. The mass
spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository
[68] with the data set identifier PXD000742 for the CN,
PXD000749 for the putamen, PXD000755 for the GPe,
and PXD000757 for the GPi.
Data handling and bioinformatic analysis
The proteins identified in this study were classified by
DAVID (Database for Annotation, Visualization and In-
tegrated Discovery) Bioinformatics Resources (v6.7) [46],
where proteins are assigned in gene ontology (GO)
terms, which rely on a controlled vocabulary for describ-
ing a protein in terms of its molecular function, bio-
logical process, or subcellular localization [69]. For
functional annotation clustering, we set the following
parameters: “Biological process and molecular function”,
high stringency and EASE p-value <0.01. PANTHER
(Protein annotation through evolutionary relationship)
classification system (http://www.pantherdb.org/) [48]
was used to perform proteome mapping analysis of BG
proteins across specific-neuronal processes. Network
analysis was performed submitting the corresponding
protein IDs to the STRING (Search Tool for the Re-
trieval of Interacting Genes) software (v.9.1) (http://
stringdb.org/) [34]. This is a large database of known
and predicted protein interactions. Proteins were repre-
sented with nodes and the interactions with continuous
lines to represent direct interactions (physical), while in-
direct ones (functional) were presented by interrupted
lines. All the edges were supported by at least a refer-
ence from the literature or from canonical information
stored in the STRING database. To minimize false posi-
tives as well as false negatives, only interactions tagged
as “high confidence” (>0.7) in STRING database were
considered. Protein/gene ID conversions were obtained
using g:profiler (http://biit.cs.ut.ee/gprofiler/gconvert.cgi)
[70] and Protein Identifier Cross-Reference tool (PICR)
(http://www.ebi.ac.uk/Tools/picr/) [71].
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